paxil: Pharmaceutical manufacturers, suppliers, and distributors

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031	NDA	Apotex Corp	60505-4517-3	30 TABLET, FILM COATED in 1 BOTTLE (60505-4517-3)	2019-03-11
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031	NDA	Apotex Corp	60505-4518-3	30 TABLET, FILM COATED in 1 BOTTLE (60505-4518-3)	2019-03-11
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031	NDA	Apotex Corp	60505-4519-3	30 TABLET, FILM COATED in 1 BOTTLE (60505-4519-3)	2019-03-11
Apotex	PAXIL	paroxetine hydrochloride	TABLET;ORAL	020031	NDA	Apotex Corp	60505-4520-3	30 TABLET, FILM COATED in 1 BOTTLE (60505-4520-3)	2019-03-11
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

This report analyzes the global supply chain for Paxil (paroxetine hydrochloride), a selective serotonin reuptake inhibitor (SSRI) antidepressant. It identifies key manufacturers, active pharmaceutical ingredient (API) producers, and discusses regulatory compliance relevant to pharmaceutical sourcing. The analysis focuses on entities involved in the production and supply of generic and branded Paxil.

Who Manufactures Paxil?

Paxil, originally developed by GlaxoSmithKline (GSK), is now primarily available as a generic medication. The manufacturing landscape includes both originators and numerous generic drug manufacturers.

Branded Paxil Manufacturer

GlaxoSmithKline (GSK): The originator of Paxil. While GSK no longer markets the branded product extensively in many regions, it remains a significant entity in the pharmaceutical manufacturing sector.

Key Generic Paxil Manufacturers

Generic Paxil production involves a wide array of pharmaceutical companies globally. These companies obtain regulatory approval for their formulations, often after the expiry of GSK's patents.

Teva Pharmaceutical Industries Ltd.: A major global generic pharmaceutical manufacturer with a significant presence in the antidepressant market. Teva produces paroxetine formulations for various markets.
Mylan N.V. (now Viatris): Viatris, formed by the merger of Mylan and Pfizer's Upjohn division, is another substantial player in the generic drug space, including paroxetine.
Lupin Limited: An Indian multinational pharmaceutical company that manufactures and markets a range of generic medications, including paroxetine.
Sun Pharmaceutical Industries Ltd.: India's largest pharmaceutical company, Sun Pharma is a significant supplier of generic drugs worldwide, including paroxetine.
Dr. Reddy's Laboratories: A prominent Indian pharmaceutical company with a global footprint, involved in the production of various APIs and finished dosage forms, including paroxetine.
Apotex Inc.: A Canadian-based pharmaceutical company specializing in generic drugs, which produces paroxetine hydrochloride tablets.
Cipla Limited: Another major Indian pharmaceutical company with a broad portfolio of generic medicines.

Who Produces Paroxetine Hydrochloride API?

The production of the Active Pharmaceutical Ingredient (API), paroxetine hydrochloride, is a critical component of the Paxil supply chain. API manufacturing is concentrated in regions with strong chemical synthesis capabilities and established regulatory frameworks.

Major API Suppliers

Divi's Laboratories Limited: An Indian company specializing in API and custom synthesis. Divi's is a known producer of paroxetine hydrochloride API.
Granules India Limited: Another Indian pharmaceutical company that manufactures APIs, intermediates, and finished dosage forms. Granules is involved in paroxetine API production.
Centrient Pharmaceuticals (formerly Synthon): A global producer of APIs and finished dosage forms, with capabilities in various therapeutic areas.
Jubilant Pharmova Limited: An integrated global pharmaceutical company that manufactures APIs, including those for central nervous system (CNS) medications.
Hubei Biocause Pharmaceutical Co., Ltd.: A Chinese manufacturer of APIs, noted for its production capacity in various pharmaceutical ingredients.
Nantong Acetic Acid Chemical Co., Ltd.: A Chinese company involved in the chemical and pharmaceutical industries, producing APIs.
ASIN-PHARMA GmbH: A German company that focuses on the development and manufacturing of APIs and intermediates.

Regulatory Compliance in Pharmaceutical Supply Chains

Suppliers of Paxil and its API must adhere to stringent regulatory standards to ensure product quality, safety, and efficacy.

Key Regulatory Bodies and Requirements

U.S. Food and Drug Administration (FDA): Oversees drug manufacturing in the United States. Manufacturers must comply with Current Good Manufacturing Practices (cGMP). Inspections ensure adherence to quality standards.
European Medicines Agency (EMA): Regulates medicines for use in the European Union. Compliance with EU GMP guidelines is mandatory.
Pharmaceuticals and Medical Devices Agency (PMDA) in Japan: The regulatory authority in Japan.
Central Drugs Standard Control Organisation (CDSCO) in India: The national regulatory body for pharmaceuticals and medical devices in India.
Therapeutic Goods Administration (TGA) in Australia: Regulates therapeutic goods in Australia.

Good Manufacturing Practices (GMP)

Quality Management Systems: Manufacturers must establish robust quality management systems encompassing documentation, validation, change control, and deviation management.
Facility and Equipment: Manufacturing facilities must be designed, maintained, and operated to prevent contamination and ensure product integrity. Equipment must be qualified and calibrated.
Personnel: Adequately trained personnel are essential for all manufacturing operations.
Process Validation: Manufacturing processes must be validated to ensure they consistently produce a product meeting predetermined specifications.
Analytical Testing: Raw materials, in-process materials, and finished products undergo rigorous analytical testing to confirm identity, strength, quality, and purity.

Drug Master Files (DMFs)

API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF provides detailed information about the API manufacturing process, facilities, and quality controls. This allows finished drug product manufacturers to reference the API's information in their own regulatory submissions without needing direct access to proprietary details.

Supplier Qualification Programs

Pharmaceutical companies maintain rigorous supplier qualification programs. This involves auditing API manufacturers and other critical suppliers to verify their compliance with cGMP and other relevant standards. Audits assess manufacturing processes, quality control systems, and overall regulatory adherence.

Supply Chain Dynamics and Risks

The global nature of pharmaceutical manufacturing presents both opportunities for cost efficiency and potential supply chain vulnerabilities.

Geographic Concentration

API Production: A significant portion of API manufacturing, including for paroxetine, is concentrated in India and China due to lower manufacturing costs and established chemical synthesis infrastructure. This concentration can create risks related to geopolitical instability, trade disputes, or localized regulatory enforcement.
Finished Dosage Form Manufacturing: While global, significant generic drug manufacturing also occurs in India, Europe, and North America.

Supply Chain Disruptions

Potential disruptions include:

Raw Material Shortages: Dependence on specific raw material suppliers can lead to shortages.
Natural Disasters and Pandemics: Events like the COVID-19 pandemic demonstrated the vulnerability of global supply chains to widespread disruptions.
Regulatory Changes: Increased scrutiny or changes in regulatory requirements in key manufacturing regions can impact supply.
Geopolitical Factors: Trade wars, tariffs, and international relations can affect the movement of goods and the cost of production.

Strategies to Mitigate Risk

Diversification of Suppliers: Utilizing multiple qualified API and excipient suppliers across different geographic regions.
Dual Sourcing: Establishing relationships with at least two primary suppliers for critical components.
Inventory Management: Maintaining strategic safety stocks of APIs and critical raw materials.
Strong Supplier Relationships: Fostering close collaboration and transparency with key manufacturing partners.
Regulatory Intelligence: Proactively monitoring and adapting to evolving regulatory landscapes in all relevant jurisdictions.

Paxil Formulations and Market Presence

Paroxetine is available in various dosage forms, primarily oral tablets and liquid suspensions. The market is dominated by generic versions, with brand-name Paxil (Paxil CR) having a reduced market share in many countries.

Dosage Forms

Tablets: Immediate-release and controlled-release formulations are common. Strengths typically range from 10 mg to 50 mg.
Oral Suspension: Liquid formulations are available, often for patients who have difficulty swallowing tablets.

Market Exclusivity and Generic Entry

The patent expiry of branded Paxil allowed for the entry of generic manufacturers, leading to increased competition and lower prices. Regulatory approval for generic versions requires demonstrating bioequivalence to the reference listed drug.

Conclusion

The supply chain for Paxil (paroxetine hydrochloride) is a complex global network involving numerous API manufacturers, predominantly in India and China, and a wide range of generic pharmaceutical companies worldwide. Regulatory compliance, particularly adherence to cGMP standards, is paramount across all manufacturing stages. Companies engaged with the Paxil supply chain must actively manage risks associated with geographic concentration and potential disruptions to ensure continuity of supply and product quality.

Key Takeaways

API Production Dominance: A substantial portion of paroxetine hydrochloride API is manufactured by companies based in India and China.
Generic Market Landscape: The finished dosage form market for Paxil is largely supplied by generic manufacturers, including Teva, Viatris, Lupin, and Sun Pharma.
Regulatory Imperative: Strict adherence to cGMP regulations from bodies like the FDA and EMA is critical for all suppliers.
Supply Chain Vulnerability: Geographic concentration of API production presents inherent risks that require proactive mitigation strategies such as supplier diversification.

FAQs

What is the primary regulatory requirement for manufacturing Paxil API? The primary regulatory requirement is adherence to Current Good Manufacturing Practices (cGMP) as defined by relevant health authorities such as the U.S. FDA, EMA, and others. This includes stringent quality control, process validation, and facility standards.
How does the process of obtaining a generic Paxil approval differ from the original branded drug? Generic drug approval, unlike the original branded drug which requires extensive clinical trials to prove safety and efficacy, primarily focuses on demonstrating bioequivalence to the innovator drug. This means showing that the generic formulation delivers the same amount of active ingredient into the bloodstream at the same rate.
Are there any specific quality concerns associated with API manufacturers in China or India? While many API manufacturers in China and India meet international quality standards, regulatory bodies like the FDA do conduct inspections and may issue warning letters or import alerts for facilities found to be non-compliant. Due diligence and robust supplier qualification programs are essential for sourcing from any region.
What is a Drug Master File (DMF) and why is it important for Paxil API suppliers? A Drug Master File (DMF) is a submission to a regulatory agency that contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. It is important for API suppliers as it allows them to provide proprietary manufacturing data directly to regulatory authorities without disclosing it to their drug product customers.
What are the common risks associated with the global supply chain for paroxetine hydrochloride? Common risks include disruptions from geopolitical events, natural disasters, pandemics, raw material shortages, and changes in regulatory policies in key manufacturing countries. The concentration of API production in specific regions, such as India and China, also represents a significant risk factor.

Citations

[1] GlaxoSmithKline. (n.d.). About GlaxoSmithKline. Retrieved from [Company Website] (Note: Specific URL omitted as it's a general company reference.) [2] Teva Pharmaceutical Industries Ltd. (n.d.). Products. Retrieved from [Company Website] [3] Viatris Inc. (n.d.). Our Products. Retrieved from [Company Website] [4] Lupin Limited. (n.d.). Product Portfolio. Retrieved from [Company Website] [5] Sun Pharmaceutical Industries Ltd. (n.d.). Global Product Presence. Retrieved from [Company Website] [6] Dr. Reddy's Laboratories. (n.d.). Global Operations. Retrieved from [Company Website] [7] Apotex Inc. (n.d.). Product Catalog. Retrieved from [Company Website] [8] Cipla Limited. (n.d.). Global Reach. Retrieved from [Company Website] [9] Divi's Laboratories Limited. (n.d.). APIs. Retrieved from [Company Website] [10] Granules India Limited. (n.d.). APIs. Retrieved from [Company Website] [11] Centrient Pharmaceuticals. (n.d.). Products. Retrieved from [Company Website] [12] Jubilant Pharmova Limited. (n.d.). APIs. Retrieved from [Company Website] [13] Hubei Biocause Pharmaceutical Co., Ltd. (n.d.). API Products. Retrieved from [Company Website] [14] Nantong Acetic Acid Chemical Co., Ltd. (n.d.). Products. Retrieved from [Company Website] [15] ASIN-PHARMA GmbH. (n.d.). Products & Services. Retrieved from [Company Website] [16] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) for Pharmaceuticals. Retrieved from [FDA Website] [17] European Medicines Agency. (n.d.). Good manufacturing practice. Retrieved from [EMA Website] [18] U.S. Food and Drug Administration. (n.d.). Drug Master Files: How to Prepare and Submit. Retrieved from [FDA Website] [19] International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use. (n.d.). ICH Harmonised Tripartite Guideline Q7: Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. Retrieved from [ICH Website]

Suppliers and packagers for paxil

paxil

Paxil Suppliers: Global Manufacturing and Sourcing Landscape